Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Clinical trial NCT01304498 · COMPLETED

Trial details

NCT number: NCT01304498
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Human Papillomavirus

Start date: 2011-02-23
Primary completion: 2011-12-20
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.